Evidence map›Paper›PMID 28874423›Full record

ArticleCirculation2017

Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.

Ben A Kappel, Michael Lehrke, Katharina Schütt, Anna Artati, Jerzy Adamski, Corinna Lebherz, Nikolaus Marx

Registry-linked trialAbstract readLetter
PubMed Publisher
In one paragraph

Article in Circulation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05719714 (Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease), which is not on this map. Cited by 81 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05719714 phase1 / phase2active not recruitingstarted 2024, after this paper: background citation

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Ran2024Enrolled18Registered outcomes5Posted comparisons0ConditionsChronic Kidney Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Kidney DiseasesArmsDapagliflozin 10 MG [Farxiga]
PMID 29166232PMID 29526832PMID 29133604PMID 3361755PMID 10716471PMID 15504931PMID 16461840PMID 18760751PMID 21262990PMID 21817129PMID 24218128PMID 25370599other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2021
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ben A KappelFrom Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Germany (B.A.K., M.L., K.S., C.L., N.M.); Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany (A.A., J.A.); Institute of Experimental Genetics, Life and Food Science Center Weihenstephan, Technische Universität München, Freising, Germany (J.A.); and German Center for Diabetes Research, Neuherberg, Germany (J.A.).
Michael LehrkeFrom Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Germany (B.A.K., M.L., K.S., C.L., N.M.); Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany (A.A., J.A.); Institute of Experimental Genetics, Life and Food Science Center Weihenstephan, Technische Universität München, Freising, Germany (J.A.); and German Center for Diabetes Research, Neuherberg, Germany (J.A.).
Katharina SchüttFrom Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Germany (B.A.K., M.L., K.S., C.L., N.M.); Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany (A.A., J.A.); Institute of Experimental Genetics, Life and Food Science Center Weihenstephan, Technische Universität München, Freising, Germany (J.A.); and German Center for Diabetes Research, Neuherberg, Germany (J.A.).
Anna ArtatiFrom Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Germany (B.A.K., M.L., K.S., C.L., N.M.); Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany (A.A., J.A.); Institute of Experimental Genetics, Life and Food Science Center Weihenstephan, Technische Universität München, Freising, Germany (J.A.); and German Center for Diabetes Research, Neuherberg, Germany (J.A.).
Jerzy AdamskiFrom Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Germany (B.A.K., M.L., K.S., C.L., N.M.); Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany (A.A., J.A.); Institute of Experimental Genetics, Life and Food Science Center Weihenstephan, Technische Universität München, Freising, Germany (J.A.); and German Center for Diabetes Research, Neuherberg, Germany (J.A.).
Corinna LebherzFrom Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Germany (B.A.K., M.L., K.S., C.L., N.M.); Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany (A.A., J.A.); Institute of Experimental Genetics, Life and Food Science Center Weihenstephan, Technische Universität München, Freising, Germany (J.A.); and German Center for Diabetes Research, Neuherberg, Germany (J.A.).
Nikolaus MarxFrom Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Germany (B.A.K., M.L., K.S., C.L., N.M.); Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany (A.A., J.A.); Institute of Experimental Genetics, Life and Food Science Center Weihenstephan, Technische Universität München, Freising, Germany (J.A.); and German Center for Diabetes Research, Neuherberg, Germany (J.A.). nmarx@ukaachen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedBenzhydryl CompoundsBiomarkersCardiovascular DiseasesDiabetes Mellitus, Type 2Energy MetabolismFemaleGlucosidesHumansMaleMetabolomicsMiddle AgedMyocardiumProspective StudiesSodium-Glucose Transporter 2 InhibitorsTreatment OutcomeBenzhydryl CompoundsBiomarkersempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitorsbranched-chain amino acidscardiovascular diseaseempagliflozinketone bodiesmetabolomicsSGTL2 inhibitorstype 2 diabetes mellitus

Identifiers

PMID28874423

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.